156 related articles for article (PubMed ID: 23401744)
1. The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells.
Fernández Massó JR; Oliva Argüelles B; Tejeda Y; Astrada S; Garay H; Reyes O; Delgado-Roche L; Bollati-Fogolín M; Vallespí MG
J Amino Acids; 2013; 2013():251398. PubMed ID: 23401744
[TBL] [Abstract][Full Text] [Related]
2. The Anticancer Peptide CIGB-552 Exerts Anti-Inflammatory and Anti-Angiogenic Effects through COMMD1.
Daghero H; Fernández Massó JR; Astrada S; Guerra Vallespí M; Bollati-Fogolín M
Molecules; 2020 Dec; 26(1):. PubMed ID: 33396282
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models.
Vallespí MG; Pimentel G; Cabrales-Rico A; Garza J; Oliva B; Mendoza O; Gomez Y; Basaco T; Sánchez I; Calderón C; Rodriguez JC; Markelova MR; Fichtner I; Astrada S; Bollati-Fogolín M; Garay HE; Reyes O
J Pept Sci; 2014 Nov; 20(11):850-9. PubMed ID: 25044757
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis reveals amino acids critical for anticancer activity of peptide CIGB-552.
Astrada S; Gomez Y; Barrera E; Obal G; Pritsch O; Pantano S; Vallespí MG; Bollati-Fogolín M
J Pept Sci; 2016 Nov; 22(11-12):711-722. PubMed ID: 27933724
[TBL] [Abstract][Full Text] [Related]
5. The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines.
Cirigliano SM; Díaz Bessone MI; Berardi DE; Flumian C; Bal de Kier Joffé ED; Perea SE; Farina HG; Todaro LB; Urtreger AJ
Cancer Cell Int; 2017; 17():42. PubMed ID: 28373828
[TBL] [Abstract][Full Text] [Related]
6. Cell Penetrating Capacity and Internalization Mechanisms Used by the Synthetic Peptide CIGB-552 and Its Relationship with Tumor Cell Line Sensitivity.
Astrada S; Fernández Massó JR; Vallespí MG; Bollati-Fogolín M
Molecules; 2018 Mar; 23(4):. PubMed ID: 29601540
[TBL] [Abstract][Full Text] [Related]
7. Antitumour peptide based on a protein derived from the horseshoe crab: CIGB-552 a promising candidate for cancer therapy.
Oliva Arguelles B; Riera-Romo M; Guerra Vallespi M
Br J Pharmacol; 2020 Aug; 177(16):3625-3634. PubMed ID: 32436254
[TBL] [Abstract][Full Text] [Related]
8. A first-in-class, first-in-human, phase I trial of CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF-κB in patients with advanced solid tumors.
Vallespi MG; Mestre B; Marrero MA; Uranga R; Rey D; Lugiollo M; Betancourt M; Silva K; Corrales D; Lamadrid Y; Rodriguez Y; Maceo A; Chaviano PP; Lemos G; Cabrales A; Freyre FM; Santana H; Garay HE; Oliva B; Fernandez JR
Int J Cancer; 2021 Sep; 149(6):1313-1321. PubMed ID: 34019700
[TBL] [Abstract][Full Text] [Related]
9. The first report of cases of pet dogs with naturally occurring cancer treated with the antitumor peptide CIGB-552.
Vallespi MG; Rodriguez JC; Seoane LC; Alvarez P; Santana H; Garay H; Cabrera IA; Espinosa JT; Reyes O
Res Vet Sci; 2017 Oct; 114():502-510. PubMed ID: 28987957
[TBL] [Abstract][Full Text] [Related]
10. Proteomic Study to Survey the CIGB-552 Antitumor Effect.
Rodríguez-Ulloa A; Gil J; Ramos Y; Hernández-Álvarez L; Flores L; Oliva B; García D; Sánchez-Puente A; Musacchio-Lasa A; Fernández-de-Cossio J; Padrón G; González López LJ; Besada V; Guerra-Vallespí M
Biomed Res Int; 2015; 2015():124082. PubMed ID: 26576414
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.
Perera Y; Costales HC; Diaz Y; Reyes O; Farina HG; Mendez L; Gómez RE; Acevedo BE; Gomez DE; Alonso DF; Perea SE
J Pept Sci; 2012 Apr; 18(4):215-23. PubMed ID: 22407768
[TBL] [Abstract][Full Text] [Related]
12. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG
Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334
[TBL] [Abstract][Full Text] [Related]
13. Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
Perera Y; Melão A; Ramón AC; Vázquez D; Ribeiro D; Perea SE; Barata JT
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471246
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines.
Benavent Acero FR; Perera Negrin Y; Alonso DF; Perea SE; Gomez DE; Farina HG
Mol Pharm; 2014 Jun; 11(6):1798-807. PubMed ID: 24773585
[TBL] [Abstract][Full Text] [Related]
15. Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide.
Garay H; Espinosa LA; Perera Y; Sánchez A; Diago D; Perea SE; Besada V; Reyes O; González LJ
J Pept Sci; 2018 Jun; 24(6):e3081. PubMed ID: 29676523
[TBL] [Abstract][Full Text] [Related]
16. HSCARG regulates NF-kappaB activation by promoting the ubiquitination of RelA or COMMD1.
Lian M; Zheng X
J Biol Chem; 2009 Jul; 284(27):17998-8006. PubMed ID: 19433587
[TBL] [Abstract][Full Text] [Related]
17. CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model.
Pérez GV; Rosales M; Ramón AC; Rodríguez-Ulloa A; Besada V; González LJ; Aguilar D; Vázquez-Blomquist D; Falcón V; Caballero E; Carvalho PC; Caldeira RS; Yang K; Perera Y; Perea SE
Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672551
[TBL] [Abstract][Full Text] [Related]
18. Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization.
Gottardo MF; Capobianco CS; Sidabra JE; Garona J; Perera Y; Perea SE; Alonso DF; Farina HG
Sci Rep; 2020 Sep; 10(1):14689. PubMed ID: 32895446
[TBL] [Abstract][Full Text] [Related]
19. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.
Perera Y; Farina HG; Gil J; Rodriguez A; Benavent F; Castellanos L; Gómez RE; Acevedo BE; Alonso DF; Perea SE
Mol Cancer Ther; 2009 May; 8(5):1189-96. PubMed ID: 19417160
[TBL] [Abstract][Full Text] [Related]
20. Comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells.
Núñez de Villavicencio-Díaz T; Ramos Gómez Y; Oliva Argüelles B; Fernández Masso JR; Rodríguez-Ulloa A; Cruz García Y; Guirola-Cruz O; Perez-Riverol Y; Javier González L; Tiscornia I; Victoria S; Bollati-Fogolín M; Besada Pérez V; Guerra Vallespi M
J Proteomics; 2015 Aug; 126():163-71. PubMed ID: 26013411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
